Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05299268
Other study ID # S-20210184
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 8, 2022
Est. completion date April 12, 2022

Study information

Verified date April 2022
Source Aalborg University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate how acute pain induced by hypertonic saline prior to exercise influence the magnitude of exercise-induced hypoalgesia after 1x3 min seated isometric knee extension exercise in healthy women. The study is a blinded randomized cross-over trial The results from the study may be of great importance to the understanding of exercise-induced hypoalgesia, and whether the presence of pain affects the effects of exercise.


Description:

Exercise is recommended to promote and maintain health and as treatment for more than 25 chronic diseases and pain conditions. The mechanisms underlying pain relief of exercise are largely unknown but may be related to the modulation of central descending pain inhibitory pathways after acute exercise bouts. Exercise-induced hypoalgesia (EIH) is typically assessed as the temporary change in pressure pain thresholds (PPT) after a short acute exercise bout and EIH is seen as a proxy of descending pain inhibitory control. In general, EIH seems hypoalgesic (functional) in asymptomatic subjects. A hyperalgesic (impaired) EIH response has been reported in different chronic pain populations, although a functional EIH response also has been reported in subgroups of knee osteoarthritis patients. This implies differences in the acute response to exercise between healthy (pain-free) subjects and chronic pain patients, but it is still unknown whether the presence of pain itself affects the pain alleviating response (i.e. the EIH response) to acute exercise. It is hypothesized that acute pain will decrease the EIH response magnitude following hypertonic saline injection compared with the control injection. This study will increase the insight into the EIH mechanisms in healthy subjects in general, and how the presence of pain affects the body's own ability to modulate pain during exercise.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date April 12, 2022
Est. primary completion date April 12, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Pain-free - Understands and writes Danish Exclusion Criteria: - Pregnancy - Previous addictive behaviour defined as abuse of hash, opioids or other euphoric substances. - Previous painful or mental illnesses, neurological or circulatory diseases in the form of heart or lung disease. - Surgery in the lower extremities within the last 12 months - Chronic or actual pain on the days of testing - Under the influence on the days of testing - Inability to cooperate

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Pain (hypertonic saline)
A bolus injection (1 ml) of hypertonic saline (5.8%) is injected into the dominant vastus medialis muscle 20 cm proximal from the basis of patella before performance of the 1x3 min Seated Isometric Knee Extension.
No pain (Isotonic saline)
A bolus injection (1 ml) of isotonic saline (0.9%) is injected into the dominant vastus medialis muscle 20 cm proximal from the basis of patella before performance of the 1x3 min Seated Isometric Knee Extension

Locations

Country Name City State
Denmark Dept. Of Health Science and Technology, Aalborg University Aalborg

Sponsors (2)

Lead Sponsor Collaborator
Aalborg University University of Southern Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Pressure pain threshold at the dominant and non-dominant thigh as well as non-dominant trapezius muscle Pressure pain threshold is measured with a handheld pressure algometer. Before and after determining maximal voluntary contraction on the fist test day and prior to saline injections
Other Rating of perceived exertion (RPE) Perceived exertion is assessed with Borg RPE scale with 6 = no exertion and 20 = maximal exertion Assessed 1, 2 and 3 minutes into the Seated Isometric Knee Extension
Other Quantifying the individual´s pain experience Quantifying the individualĀ“s pain experience will be assessed using the Pain Catastrophizing Scale (PCS) at the first session. The pain catastrophizing scale have 13 sentences regarding pain-related thoughts. Participants are asked to indicate how well each sentence applies for them: 0 = not at all, 1 = to a slight degree, 2 = to a moderate degree, 3 = to a great degree and 4 = all the time. A higher score is worse Baseline
Other Pain experience Participants will be interviewed at the end of the study regarding the experience of pain during the study. The interview will be conducted after all other experimental procedures have been completed. Day 3 (within 2-3 weeks of the initial session)
Primary Change in pressure pain threshold will be assessed over the dominant quadriceps muscle Between group comparison of the primary outcome, which is change in pressure pain threshold over the dominant quadriceps muscle before and after performing seated isometric knee extension.
Pressure pain threshold is measured with a handheld pressure algometer.
Baseline, Day 2 (within 1 week of baseline), Day 3 (within 1 week of Day 2)
Secondary Pressure pain threshold at the non-dominant quadriceps muscle and non-dominant trapezius muscle Between group comparison of the secondary outcome, which is change in pressure pain threshold at the non-dominant quadriceps muscle and non-dominant trapezius muscle from before Seated Isometric Knee Extension to after Seated Isometric Knee Extension.
Pressure pain threshold is measured with a handheld pressure algometer.
Baseline, Day 2 (within 1 week of baseline), Day 3 (within 1 week of Day 2)
Secondary Pain Intensity in dominant thigh Pain intensity is assessed with numerical rating scales with 0 = no pain and 10 = maximal pain. Assessed before and immediately after hypertonic and isotonic saline injection as well as 1, 2 and 3 minutes into the Seated Isometric Knee Extension, and immediately after the end of the seated isometric knee extension
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1